The GDP-fucose transporter SLC35C1 critically regulates the fucosylation of glycans. Elucidation of its structurefunction relationships remains a challenge due to the lack of an appropriate mutant cell line. Here we report a novel Chinese hamster ovary (CHO) mutant, CHO-gmt5, generated by the zinc-finger nuclease technology, in which the Slc35c1 gene was knocked out from a previously reported CHO mutant that has a dysfunctional CMP-sialic acid transporter (CST) gene (Slc35a1). Consequently, CHOgmt5 harbors double genetic defects in Slc35a1 and Slc35c1 and produces N-glycans deficient in both sialic acid and fucose. The structure-function relationships of SLC35C1 were studied using CHO-gmt5 cells. In contrast to the CST and UDP-galactose transporter, the C-terminal tail of SLC35C1 is not required for its Golgi localization but is essential for generating glycans that are recognized by a fucose-binding lectin, Aleuria aurantia lectin (AAL), suggesting an important role in the transport activity of SLC35C1. Furthermore, we found that this impact can be independently contributed by a cluster of three lysine residues and a Glu-Met (EM) sequence within the C terminus. We also showed that the conserved glycine residues at positions 180 and 277 of SLC35C1 have significant impacts on AAL binding to CHO-gmt5 cells, suggesting that these conserved glycine residues are required for the transport activity of Slc35 proteins. The absence of sialic acid and fucose on Fc N-glycan has been independently shown to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect. By combining these features into one cell line, we postulate that CHO-gmt5 may represent a more advantageous cell line for the production of recombinant antibodies with enhanced ADCC effect.
Introduction
Glycosylation of proteins and lipids takes place in the lumen of endoplasmic reticulum (ER) and Golgi. It requires a range of activated nucleotide sugars, such as UDP-GlcNAc, UDP-galactose, CMP-sialic acid and GDP-fucose, as substrates for the extension of glycans. These nucleotide sugars are produced in the cytosol or nucleus and have to be actively transported across the Golgi membrane by a dedicated family of transporter proteins, termed nucleotide sugar transporters (NSTs or Slc35 family of proteins; Hirschberg et al. 1998; Ishida and Kawakita 2004) .
NST proteins are type III membrane proteins containing multiple membrane-spanning helices. Genetic defects in several NSTs have been linked to a rare class of diseases called congenital disorder of glycosylation (CDG) (Jaeken and Matthijs 2007) , suggesting important roles of NSTs in development (Liu et al. 2010) . Due to the difficulty in determining the structure of type III membrane proteins, structurefunction relationships of NST are often established by the mutagenesis of putative key elements , domain swap between different transporters (Aoki et al. 1999 (Aoki et al. , 2001 (Aoki et al. , 2003 or analyzing the mutations in glycosylation mutant cells, in particular the Chinese hamster ovary (CHO) Lec mutants generated by Stanley and co-workers (Patnaik and Stanley 2006) as well as cells from CDG patients (Lubke et al. 2001; Luhn et al. 2001; Martinez-Duncker et al. 2005) . The analysis usually requires a heterologous system such as yeast that lacks such NSTs or CHO glycosylation mutants with genetic defects in these NSTs.
The GDP-fucose transporter (Gfr) SLC35C1 was first identified by genetic complementation analyses based on samples from CDG-IIc patients (Lubke et al. 2001; Luhn et al. 2001) . Defects in this gene have been associated with leukocyte adhesion deficiency II, alias CDG-IIc. The amino acid sequence of SLC35C1 shows a substantial level of conservation with a CMP-sialic acid transporter (CST, or Slc35a1) and a † These authors contributed equally to this work.
UDP-galactose transporter (UGT or Slc35a2; Lubke et al. 2001; Luhn et al. 2001) . It was predicted to contain 10 transmembrane helices with both N and C termini present in the cytosolic side, similar to the topology of CST which was experimentally established (Eckhardt et al. 1999 ). However, elements that are critical for the localization and activity of SLC35C1 remain poorly understood.
Recently, the Drosophila gene CG3774 was found to encode a protein (Efr) that shows the in vitro transport activity for GDP-fucose in addition to UDP-GlcNAc and UDP-xylose (Ishikawa et al. 2010 ). This protein is localized to the ER depending on its C-terminal KKXX ER retention/retrieval sequence. However, Efr was shown to be required for the fucosylation of Notch but not N-glycans. In human, another Notch O-fucosylation-related protein has been identified as SLC35C2 (Lu et al. 2010 ). This protein is localized to ERGIC/cis-Golgi compartments and was shown to positively regulate the O-fucosylation of Notch. Overexpression of SLC35C2 was shown to compete with SLC35C1 and have an inhibitory effect on the formation of the Lewis-X structure but imposes a marginal effect on the core fucosylation of N-glycans (Lu et al. 2010) . Therefore, despite the existence of multiple putative Gfrs, SLC35C1 is essential for the core fucosylation of N-glycans.
It is now widely recognized that the removal of the core fucose from the N-glycans attached to Asn 297 of human IgG1 significantly enhances its binding to its receptor, FcγIIIa, and thereby dramatically improves antibody-dependent cellular cytotoxicity (ADCC; Shields et al. 2002; Shinkawa et al. 2003) . Recent reports have shown that the removal of sialic acid from IgG1 also enhanced ADCC in vivo (Kaneko et al. 2006; Anthony et al. 2008) . We have reported a lectin-resistant CHO mutant line that has a dysfunctional CST (Lim et al. 2008) . As a result, glycoproteins produced by this cell line are completely free of sialic acid. The mutant line was originally named MAR-11 and has since been renamed as CHO-gmt1, for CHO glycosylation mutant-1. Here, we use the zinc-finger nuclease (ZFN) technology to knock out the Slc35c1 gene from the CHO-gmt1 cells. The resultant cell line, CHO-gmt5, was shown to produce N-glycans free of sialic acid and fucose. We ultimately aim to test whether an IgG1 lacking both fucose and sialic acid would perform even better in activating ADCC. However, in this study, we have focused our efforts on using this mutant cell line to study the structurefunction relationships of SLC35C1. To this end, we generated a set of human SLC35C1 expression constructs harboring mutations at different regions. Different Gfr SLC35C1 mutants were expressed in CHO-gmt5 cells, and the fucosylation of cell surface glycans in the transfected cells was analyzed using a fucose-specific lectin, Aleuria aurantia lectin (AAL). Using this system, we successfully identified elements located in different regions of SLC35C1 with significant impacts on glycan fucosylation, suggesting a possible role of such elements in determining the transport activity of SLC35C1.
Results
ZFNs generated by the combinatorial selection-based methods may have high DNA-binding affinity and low toxicity (Maeder et al. 2008) . However, it requires large randomized libraries and the selection expertise that only a few labs possess. We engineered a pair of ZFNs to target the Gfr (Slc35c1) gene in CHO cells using a simplified "modular assembly" strategy. Each zinc finger in our ZFNs was designed based on publicly available information described in the literature. We have demonstrated that this method can be a viable approach for researchers who do not have the expertise to perform a combinatorial selection.
Design of ZFNs to target the Gfr Slc35c1 in CHO cells
Analysis of the open reading frame of Chinese hamster Gfr Slc35c1 by the web-based ZiFiT program provided by the Zinc Finger Consortium [ZiFiT: software for engineering zinc finger proteins (V3.0)] at http://bindr.gdcb.iastate.edu/ZiFiT/ (Sander et al. 2007 ) identified one potential target site in the first exon of the Gfr Slc35c1 coding region(5′-tAACCTCTGCCTCAAGTACGTAGGGGTGGCCt-3′; Figure 1A ). Two potential binding sites for ZFNs in this sequence (underlined) are separated by 6 bp which is the optimal distance for cleavage by ZFNs. This sequence perfectly matches the ideal target sequence for 4-fingered ZFNs which is: 5′-NNCNNCNNCNNCxxxxxxGNNGNNGNNGNN-3′. It allows each zinc-finger motif in the left ZFN and the right ZFN to bind a 5′-GNN-3′ DNA triplet ( Figure 1A) as it has been shown that the 5′-GNN-3′ triplets generally show high affinities for proper zinc fingers (Segal et al. 1999; Dreier et al. 2000; Liu et al. 2002) . The "modular assembly" method was used to generate specific ZFNs for targeting the Slc35c1 gene in CHO cells. The structural scaffold for the ZFNs was adopted from previous publications (Urnov et al. 2005; Doyon et al. 2008) . The DNA-binding domains of the two ZFNs against this site were assembled using an archive of engineered zinc-finger motifs collected from previous publications, mainly by Barbas's group and Sangamo BioSciences Inc. (Segal et al. 1999; Dreier et al. 2000; Liu et al. 2002) . The amino acid sequences that determine the binding specificity of the ZFNs are: for ZFN-L (5′GAG GCA GAG GTT′3 target): finger 1 (for GTT), TSGSLVR; finger 2 (for GAG), RSDNLAR; finger 3 (for GCA), QSGSLTR; finger 4 (for GAG), RSDNLAR; and for ZFN-R (5′GTA GGG GTG GCC′ 3 target): finger 1 (for GCC), ERGTLAR; finger 2 (for GTG), RSDALAR; finger 3 (for GGG), RSDHLSR, finger 4 (for GTA), QSGALAR. The complete design of the zinc fingers in the left and the right ZFN is shown in Figure 1B .
Generation and identification of SLC35C1-deficient CHO cells CHO-gmt1 (formerly MAR-11) cells were transfected with the vectors that express the ZFNs to bind the ZFN-L and ZFN-R shown in Figure 1A . Two days after transfection, single cells were seeded in one 96-well plate for clone isolation. Genomic DNA from each single clone was isolated and the Gfr target locus was amplified by specific polymerase chain reaction (PCR) primers (5′-GGCGCCTCTGAAGCGG TCCAGGATCC and 5′-GCCACATGTGAGCAGGGCATAG AAGG). A 520-bp PCR product was generated from the wildtype CHO genomic sequence which can be digested by a restriction enzyme SnaBI (TAC|GTA) at the ZFN restriction site ( Figure 1A ) to give rise to a smaller fragment of 114 bp and a larger fragment of 406 bp. In the event that a deletion mutation has occurred at the targeted site of ZFNs, the PCR product may become resistant to the restriction enzyme. However, for insertion mutants, the PCR products have to be sequenced in order to identify the mutation. DNA sequencing results for the PCR products of the isolated clones showed several random deletion and insertion mutations around the ZFN target site ( Figure 1C ). Clones C, D, E, F, G, H and M represent different single clones in which mutations have been identified. While clone D, F, G and M each has one mutated allele, they still possessed one wild-type allele of the Slc35c1 gene. As a result, these cells still express fucose-containing glycoproteins as suggested by the positive staining of a fucose-specific lectin, AAL (data not shown). Two alleles of the Slc35c1 gene in clone C were mutated, resulting in one deletion mutation (C1) and one insertion mutation (C2). Unfortunately, this clone had three alleles of the Slc35c1 gene and the third was not mutated (Supplementary data, Figure S1 ). Therefore, clone C still possessed the wild-type phenotype in terms of AAL binding (data not shown). Interestingly, the inserted DNA fragment shown in C2 came from the ZFN expression vector used in this experiment. Clone E had two alleles of the Slc35c1 gene and both were mutated, each with a deletion mutation. E1 has a 3-bp deletion. As a result, two amino acids in the Gfr protein ( 137 KY 138 ) have been replaced by one N residue. E2 has a 40-bp deletion that results in a prematurely truncated SLC35C1 product of 172 amino acids. The PCR product of this clone was found to be resistant to the restriction enzyme SnaBI because the recognition site (TAC|GTA) in both alleles had been abolished by the deletions. This clone, named CHO-gmt5, was used for further fucosylation analyses.
Endogenous and recombinant N-glycans produced by CHO-gmt5 cell are free of fucose Lectin staining was performed to gain insights into the glycan terminal structures on CHO-gmt5 cells (Figure 2A ). Parental CHO-gmt1 cells and wild-type CHO-K1 cells were also included in this analysis. Cells were labeled with two lectins, peanut agglutinin (PNA) that recognizes terminal β-linked galactose residues and AAL that recognizes a fucose residue. Although AAL is known to act as a "universal" fucosespecific lectin, the biochemical characterization of its binding specificity suggested a strongest affinity toward core fucose and Lewis-X epitope on N-glycans (Matsumura et al. 2007; Iskratsch et al. 2009; Bergstrom et al. 2012) . CHO-K1 cells are negative for PNA staining due to the capping of galactose residues by sialic acids. They are positive for AAL binding because of the abundant fucosylation of N-glycans. In contrast, CHO-gmt1 is positive not only for AAL, but also for PNA due to the genetic defect in CST leading to the production of galactose-terminated N-glycans. As expected, CHO-gmt5 was shown to be positive for PNA. However, the binding of AAL to CHO-gmt5 cells was dramatically diminished with very weak staining signals left. It was noted that the weak staining of CHO-gmt5 cells by AAL was also Structure-function analysis of GDP-fucose transporter present when the AAL-fucose interaction was blocked by 10 mg/mL of L-fucose (Supplementary data, Figure S2 ). Therefore, this weak background is most likely caused by the non-specific binding of AAL, which is consistent with a previous report supporting such non-specific interaction (Matsumura et al. 2007 ). Hence, the diminished binding of AAL to CHO-gmt5 cells is suggestive of fucosylation deficiency in the cell line.
Recombinant erythropoietin (EPO)-Fc fusion protein produced in CHO-gmt1 and CHO-gmt5 was purified by a protein A column, and the N-linked glycans liberated by N-glycosidase F (PNGase F) were analyzed by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) as previously described (Lim et al. 2008; Goh et al. 2010 ) and the mass spectra are as shown in Figure 2B . The N-glycans isolated from CHO-gmt1 were mostly fucosylated, and the , CHO-gmt1 and CHO-gmt5 cells were seeded on glass coverslips, cultured overnight before being fixed and permeabilized. Terminal galactose residues were detected using FITC-conjugated PNA (colored green). Fucose residues were detected using biotinylated AAL and AlexaFluor 647-conjugated streptavidin ( pseudo-colored red). Nuclei were stained by Hoechst 33342 and colored blue. (B) N-Glycans isolated from recombinant EPO-Fc produced in CHO-gmt1 and CHO-gmt5 cells were analyzed by MALDI-TOF. The N-glycans produced by CHO-gmt1 were mostly fucosylated, and the dominant species were the asialo, core-fucosylated galactosyl bi-, tri-and tetra-antennary glycans. However, the N-glycans produced by CHO-gmt5 were the asialo, afucosylated galactosyl bi-, tri-and tetra-antennary glycans. The three minor peaks at m/z = 2244.0, 2693.3 and 3142.5 indicated by asterisks in the CHO-gmt5 sample correspond to contaminating fucosylated glycan species most likely from the culture media (Supplementary data, Figure S3 ).
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dominant species were the asialo, core-fucosylated galactosyl bi-, tri-and tetra-antennary glycans. In contrast, the dominant species isolated from CHO-gmt5 were the asialo, afucosylated galactosyl bi-, tri-and tetra-antennary glycans, correspondingly. Minor peaks corresponding to fucosylated species were observed in the CHO-gmt5 sample at residual levels (indicated by asterisks at m/z = 2244.0, 2693.3 and 3142.4), but these peaks were also present in the control sample (Supplementary data, Figure S3 ). In this experiment, the conditioned medium collected from untransfected CHO-gmt5 cells that did not express EPO-Fc was subjected to the same protein A purification procedure, PNGase F treatment and MALDI-TOF analysis. The presence of residual amounts of fucosylated glycans in the control sample suggests that the small amounts fucosylated glycans in the CHO-gmt5 medium ( Figure 2B ) may be a result of the presence of serum in the culture medium. These data clearly demonstrated that glycoproteins expressed on the cell surface of, or secreted by, CHO-gmt5 cells are free of fucose due to the mutations of both alleles of the Slc35c1 gene.
The human Gfr SLC35C1 is localized to the medialand trans-Golgi The Caenorhabditis elegans Golgi Gfr and human SLC35C1 have been shown to be localized to the Golgi apparatus (Luhn et al. 2001) . To ascertain the distribution of SLC35C1 in the Golgi, we transiently expressed hemagglutinin (HA)-tagged human SLC35C1 in HeLa cells and analyzed its distribution by immunofluorescence microscopy and compared its localization pattern with defined Golgi cisternal markers. Cells expressing the moderate level of heterologous HA-SLC35C1 were analyzed and representative images were shown in Figure 3 . HA-SLC35C1 did not show co-localization with cis-Golgi marker GM130 or with trans-Golgi network (TGN) marker TGN46. Partial co-localization was detected with medial-Golgi marker mannosidase II (ManII), and a high degree of co-localization was seen with trans-Golgi marker B4GalTI. This indicates that at steady state, the majority of SLC35C1 protein is localized to the trans-Golgi, whereas a smaller fraction is localized to the medial-Golgi. This observation is consistent with the distribution pattern of CST (SLC35A1) in HeLa cells (Zhao et al. 2006 ).
The cytosolic C-terminal tail sequence of SLC35C1 is critical for its activity but not localization to the Golgi The cytosolic C-terminal tail sequence of CST has been shown to be involved in localization and Golgi-targeting (Zhao et al. 2006; Lim et al. 2008) . To determine if this feature is conserved in SLC35C1, we made a series of constructs encoding N-terminal HA-tagged human SLC35C1 variants with deletions in the C-terminal tail region ( Figure 4A ). The constructs were transfected into CHO-gmt5 cells. Two days after transfection, cells were fixed and stained with the anti-HA antibody to determine the localization of the SLC35C1 variants. Cells were counter-stained by biotinylated AAL followed by AlexaFluor 647-conjugated streptavidin as a readout for fucosylation and an indirect readout for SLC35C1 activity. Only cells expressing the moderate level of HA-SLC35C1 variants were analyzed. Multiplex fluorescent images were taken at constant imaging parameters to allow qualitative comparison of AAL binding. Under such conditions, cells expressing the same SLC35C1 variant showed a highly consistent SLC35C1 localization pattern and AAL-mediated fluorescence intensity. Representative images were shown in Figure 4B . The expression of a full-length HA-tagged human SLC35C1 (FL) restored the fucosylation in transfected CHO-gmt5 cells as evident by the strong AAL fluorescence intensity, in both the Golgi and plasma membrane regions. The deletion of amino acids 341-364 (ΔC-tail) did not change the Golgi localization of SLC35C1. However, AAL fluorescence intensity was greatly reduced. The partially retained Golgi staining by AAL could be due to higher glycoprotein concentration in the Golgi, which serves as a sorting station for secreted and membrane proteins, whereas the much larger surface area of plasma membrane "diluted" the AAL signal. Consistent with this argument, FACS analysis of cell surface fucosylation by AAL staining shows that cells transfected with the ΔC-tail construct were essentially free of fucose at the cell surface ( Figure 4C ). The diminished rescue of fucosylation suggests that this sequence is critical for the fucosylation function of SLC35C1. Since the deletion of this sequence did not change the localization of SLC35C1, it is most likely that this sequence contains essential elements for the transport activity of SLC35C1. Replacing this sequence with the analogous tail sequence of the human CST (CST-tail) did not restore the fucosylation, suggesting that, unlike CST, the C-terminal tail of SLC35C1 is essential for its activity. To narrow down to the critical amino acid residue (s), we made two more deletions within the SLC35C1 C-tail region, amino acids 356-364 (ΔCT1) and 341-355 (ΔCT2). Both variants exhibited a similar Golgi-localization pattern but striking difference in AAL fluorescence intensity. Cells expressing ΔCT1 showed AAL intensity comparable with that of the FL-transfected cells, suggesting that amino acids 356-364 are dispensable for the in vivo activity of SLC35C1. However, cells expressing ΔCT2 were negative for AAL binding, except for a basal level of fluorescence in the Golgi area. This result indicates that amino acids 341-355 are critical for the activity of SLC35C1. In addition to analyzing the lectin-stained cells under the microscope, we also employed fluorescence-activated cell sorting (FACS) to examine the cell surface fucosylation to quantitatively compare the relative activities of different SLC35C1 variants ( Figure 4C and D) . Constructs encoding SLC35C1 variants were transfected into CHO-gmt5 cells. Two days after transfection, cells were fixed but not permeabilized to allow the specific labeling of cell surface fucose residues by AAL. The SLC35C1 construct bearing a T308R mutation, a point mutation previously reported in a CDG-IIc patient (Lubke et al. 2001) , was included as a negative control. Cells transfected with the FL construct typically show 15-20% in the AAL-positive region ( Figure 4C ). This percentage was used to define 100% SLC35C1 activity ( Figure 4D ). Under such conditions, the activity of SLC35C1 T308R is close to zero. Consistent with the lectin-staining results, ΔC-tail and CST-tail SLC35C1 variants failed to restore the cell surface fucosylation. ΔCT1 showed an activity comparable with FL, whereas ΔCT2 mutant completely lost its activity.
Structure-function analysis of GDP-fucose transporter 344 EM 345 and a cluster of three Lys residues in the C-terminal tail of SLC35C1 have significant impacts on its activity To pinpoint the exact amino acid residue critical for SLC35C1 activity in the ΔCT2 deletion region, a series of mutant SLC35C1 constructs were generated by replacing each individual amino acid in this stretch with a Gly residue. These constructs were then expressed in CHO-gmt5 cells and analyzed by immunofluorescence microscopy for their subcellular localization and AAL staining for SLC35C1 activity. All these SLC35C1 mutants were localized to Golgi and shown to be fully functional as evident by strong AAL fluorescence intensity (Supplementary data, Figure S4) . Therefore, the impact of ΔCT2 may be contributed by a combination of amino acid residues, the region from 341 to 355 instead of any single amino acid residue.
Yoda and co-workers identified a series of Lys residues in the C-tail region of yeast GDP-mannose transporter (GMT) involved in ER retrieval by binding to COPI coatomer (Abe et al. 2004 ). Because such an Lys cluster is conserved in many NST proteins, they speculated a general role of such Lys cluster in ER-Golgi trafficking of NST proteins. The human SLC35C1 is one of such NST proteins. SLC35C1 contains four Lys residues, three of which are located in the ΔCT2 deletion region and are conserved in SLC35C1 orthologs in many other species (Supplementary data, Figure S5 ). We mutated these three Lys to three Gly residues (3K/3G construct illustrated in Figure 5A ) to assess their involvement in SLC35C1 localization and activity. Immunofluorescence staining results showed that mutating these three Lys to three Gly residues did not change its Golgi localization ( Figure 5B ). However, the 3K/3G mutation significantly reduced the transport activity of SLC35C1 as the AAL binding was drastically decreased, especially in the area outside the Golgi. The more pronounced Golgi staining by AAL could be due to higher steady-state concentration of glycoconjugates in the Golgi during the sorting process. The activity of SLC35C1 was Fig. 3 . Localization of HA-SLC35C1 within the Golgi. HA-tagged human SLC35C1 was transiently transfected into HeLa cells and detected by a monoclonal anti-HA antibody (colored green). Golgi compartments were stained by antibodies specific for defined Golgi markers, GM130 (cis-Golgi), ManII (medial-Golgi), B4GalT1 (trans-Golgi) and TGN46 (trans-Golgi network or TGN). All Golgi markers were colored red. Nuclei were stained by Hoechst 33342 and colored blue. The boxed areas in the merged images were enlarged and shown on the right. Scale bar: 20 µm. P Zhang et al. Fig. 4 . The cytosolic C-terminal tail sequence, and more specifically amino acids 341-355, is essential for SLC35C1 activity in fucosylation but not its localization to the Golgi. (A) The schematic representation of SLC35C1 constructs with different tail sequences. FL, full-length human SLC35C1; ΔC-tail, SLC35C1 with a deletion from amino acids 341-364; CST-tail, replacement of amino acids 341-364 with the C-terminal sequence (amino acids 317-336 according to CST numbering) of CST; ΔCT1, SLC35C1 with a deletion of amino acids 356-364; ΔCT2, SLC35C1 with a deletion of amino acids 341-355. All SLC35C1 constructs were N-terminally tagged with an HA epitope (shown as black boxes). Predicted transmembrane regions are shown as gray boxes. (B) Immunofluorescence and lectin-staining analyses for localizations and activities of SLC35C1 variants. CHO-gmt5 cells seeded on glass coverslips were transfected with an SLC35C1 construct. Heterologous SLC35C1 was detected by a monoclonal HA antibody and colored green. Golgi was marked by antibody specific for giantin and colored red. Fucose residues were detected by biotinylated AAL and AlexaFluor 647-conjugated streptavidin. Nuclei were stained by Hoechst 33342 and colored blue. Scale bar: 20 µm. (C) FACS analysis of cell surface fucosylation. CHO-gmt5 cells were transfected with an SLC35C1 construct and fixed without a permeabilization step 2 days after transfection. Cell surface fucose residues was labeled by biotinylated AAL and Cy3-conjugated streptavidin. FACS analysis was performed in duplicates on a BD LSR II analyzer and representative results were shown. In each histogram plot, the shaded area shows negative control (untransfected CHO-gmt5 incubated with biotinylated AAL and Cy3-conjugated streptavidin). Structure-function analysis of GDP-fucose transporter reduced, AAL staining of the Golgi area remained strong, in contrast to that of the plasma membrane where the larger surface area diluted the glycoconjugates. Consistent with this argument, the FACS analysis of cell surface fucosylation without cell membrane permeabilization demonstrated that the fucosylation of CHO-gmt5 cells transfected with the 3K/3G construct was reduced by 50% ( Figure 5C and D) .
The sequence alignment analysis of the SLC35C1 proteins identified in all the species so far in the database shows the conservation of the 344 EM 345 motif (Supplementary data, Figure S5 ). To test if this conserved EM motif is involved in the activity of SLC35C1, we made an EM/GG mutation by replacing the conserved EM motif with two Gly residues ( Figure 5A ). The EM/GG construct was expressed in CHO-gmt5 cells and found to be localized to Golgi ( Figure 5B ). The activity of this variant was analyzed by lectin staining and FACS. Cells expressing EM/GG variant showed AAL fluorescence mainly in the Golgi area ( Figure 5B) . Consistently, the cell surface fucosylation was found to be greatly reduced when compared with cells transfected with the FL construct ( Figure 5C and D) . To test if the EM and the Lys cluster are two inter-dependent elements for the SLC35C1 activity, we made an additional mutant construct by replacing the C-terminal sequence of SLC35C1 downstream of the 344 EMK 346 motif with the analogous region from the CST ( Figure 5A , shown as EM-CST tail) and analyzed its localization and activity in CHO-gmt5 cells. This SLC35C1 variant maintained its Golgi localization and did not show any compromised activity in AAL binding ( Figure 5B-D) . Comparing the activity of the mutant EM-CST tail ( Figure 5 ) and that of the mutant CST tail (Figure 4 ) also suggests an important role for the EM motif. Therefore, the conserved C-terminal Lys cluster and the EM sequence are two independent elements required for the activity of SLC35C1. Figure 4C . (D) Quantification of FACS results. Procedures were described as in Figure 4D .
Structure-function analysis of GDP-fucose transporter
Three conserved Gly residues in the transmembrane helices have differential impacts on the activity of SLC35C1 Previously, we identified four pairs of Gly in the transmembrane helices of CST critical for its transport activity (Lim et al. 2008) . The multiple sequence alignment of SLC35C1, CST and UGT proteins in human and Chinese hamster show that the first Gly in the first, third and fourth pairs are conserved ( Figure 6A ). To ascertain the involvement of these three conserved Gly residues in the activity of SLC35C1, we mutated individual Gly to Ile or Tyr. The transfection experiments showed that mutating any Gly to a bulky amino acid Ile or Tyr did not alter the Golgi localization of SLC35C1. However, these mutants displayed dramatic difference in rendering AAL binding to the transfected cells ( Figure 6B ): the G180I mutation resulted in a substantial decrease in AAL fluorescence intensity, whereas G180Y almost completely abolished AAL fluorescence outside Golgi; G198I and G198Y did not affect the AAL binding, whereas both G277I and G277Y mutations render the SLC35C1 non-functional as evidenced by the loss of AAL fluorescence even in the Golgi area. The lectin-staining results were verified by FACS ( Figure 6C and D) . Consistently, G180I mutation impaired the activity of SLC35C1, whereas a more bulky amino acid, Tyr, at this position almost completely diminished the activity of SLC35C1. Gly 198 is dispensable for SLC35C1 activity as substitution with Ile or Tyr did not make a significant change in cell surface fucosylation. Gly 277 was most sensitive to mutation as a substitution with Ile completely abolished cell surface fucosylation.
Discussion
Elucidating the structure-function relationships of NSTs remains a challenge due to the difficulty in solving the threedimensional structures of such type III transmembrane proteins. In this study, we generated a new CHO mutant, CHO-gmt5, in which the Gfr gene was inactivated by the ZFN technology. The CHO-gmt5 cell line was subsequently used as the host cell for studying the structure-function relationships of Gfr.
NST proteins typically contain 6-10 membrane-spanning helices with both the N and C termini facing the cytosol. The role of the C-terminal tail in the trafficking and localization of NST proteins is well established for mouse CST (Zhao et al. 2006) , human UGT (Kabuss et al. 2005 ) and yeast GMT (Gao and Dean 2000; Abe et al. 2004) . Several localization or trafficking-related motifs have been identified in the C-terminal tail region of these transporters. These include the ER-export motif (II and GV in the context of mouse CST; Zhao et al. 2006) , ER-retention signal (KXK motif in the context of human UGT2; Kabuss et al. 2005 ) and ER-retrieval sequence (Lys cluster in the C-terminal tail in the context of yeast GMT; Abe et al. 2004 ). The human SLC35C1 also terminates with a GV sequence at its C terminus. However, the GV sequence of SLC35C1 does not seem to function as an ER export signal as the deletion of the C terminus does not change the localization of the SLC35C1 in CHO-gmt5 ( Figure 4B ) and HeLa cells (data not shown). Surprisingly, the C-tail deleted, Golgi-localized SLC35C1 mutant almost completely lost its activity in terms of fucosylation. In contrast, the C terminus of CST, although critical for its localization, was found to be dispensable for its transport activity (Zhao et al. 2006; Lim et al. 2008) . In addition, the transport activity of human UGT was also shown to be independent of the C-terminal tail (Aoki et al. 1999) .
The cluster of Lys in the C-terminal tail region of yeast GMT was shown to interact with COPI coatomer and prevents GMT from accumulating in the non-Golgi vacuolar structures (Abe et al. 2004) . Interestingly, the mutation of the conserved Lys cluster in the C-terminal region of human SLC35C1 did not alter its localization to the Golgi (Figure 5B ), but significantly reduced its activity ( Figure 5C ). The molecular mechanism, however, remains unknown. One possible explanation is that the C terminus of human SLC35C1 may be involved in interacting with the substrate, GDP-fucose.
Our results demonstrated that despite the substantial sequence similarity between different NSTs, functions of the less-conserved C-terminal tail region seem to have diverged during evolution. On the other hand, although it is practically impossible to deduce the specificity of a particular NST based on its primary sequence (Berninsone and Hirschberg 2000) , residues that are conserved among different transporters can provide hints for elements that are critical for the function of different NSTs. Here, we have identified a conserved two-amino-acid motif (EM), which is present in the C-terminal region of all the Gfrs, from Drosophila to human. The finding suggests that the EM may play an important role for SLC35C1. Indeed, mutating the EM sequence to GG significantly reduced the staining signal by AAL, suggesting a reduced activity for the transporter.
Membrane-spanning helices have also been shown to have dramatic impact on the activity and specificity of NST. Domain-swap experiments have shown that different transmembrane helices are utilized for CST and UGT (Aoki et al. 2001 (Aoki et al. , 2003 . We have noticed that Gly residues are rich in certain areas of the helices. Some of these Gly residues are conserved in many NST proteins by a sequence alignment analysis (data not shown). One plausible hypothesis is that these Gly residues, due to the lack of side chain, contribute to the formation of transmembrane channels to allow for the passage of nucleotide sugars. This idea was tested in our previous work with CST (Lim et al. 2008; Chan et al. 2010) . We showed that the mutation of four pairs of Gly to Ala or Ile dramatically impair the transport activity of CST. Our results from SLC35C1 further support this notion. We noted that the first Gly residues in the first, third and four Gly pairs are conserved in SLC35C1, CST and UGT. However, these Gly residues have different impacts on the activity of SLC35C1: the Gly located in helix 5 has partial effect on fucosylation, Gly located in helix 6 is dispensable, whereas Gly located in helix 8 is essential (Figure 6 ). Interestingly, the Gly pair in helix 8 of CST was also shown to have the strongest impact on CST activity (Lim et al. 2008) . Therefore, the conserved Gly residues in the transmembrane helices are generally essential elements for the transport activity of NSTs instead of determinants of their specificities.
Biochemical and cellular analyses of Drosophila Efr (Ishikawa et al. 2010 ) and human SLC35C2 (Lu et al. 2010) revealed a role in maintaining the optimal O-fucosylation of Notch. Both studies showed that the fucosylation of N-glycans were predominantly regulated by SLC35C1 instead of the two aforementioned proteins. Interestingly, the Drosophila Efr was found to be localized to ER and SLC35C2 localized to ERGIC/cis-Golgi, which are early compartments along the secretory pathway. In this study, we found that SLC35C1 is mainly localized to the trans-Golgi and to a lesser extent to the medial-Golgi (Figure 3) . Therefore, the spatial segregation of Efr/SLC35C2 and SLC35C1 could provide a plausible explanation for the regulation of Notch O-fucosylation by Efr and SLC35C2, which takes place pre-Golgi, and does not positively affect the core fucosylation of N-glycans, which takes place in the medialand trans-Golgi. Nevertheless, targeting SLC35C1 is necessary and sufficient for regulating the core fucosylation of N-glycans at the membrane transport level.
The absence of core fucose on Fc N-glycan has been shown to enhance the ADCC effect of IgG1 (Shields et al. 2002; Shinkawa et al. 2003) . A CHO Slc35c1−/− cell line has been generated by homologous recombination and used as a host cell line for the production of fucose-free recombinant antibody (Ishiguro et al. 2010) . The absence of sialic acid on Fc N-glycan is also favorable for ADCC effect (Kaneko et al. 2006; Anthony et al. 2008) . It is tempting to speculate that the absence of both fucose and sialic acid will offer combinatorial enhancement to the ADCC effect. Our CHO-gmt5 with double-genetic defects in SLC35C1 and CST (SLC35A1) is capable of producing recombinant glycoproteins free of fucose and sialic acid and, thus, has the potential application for the production of recombinant antibodies with improved ADCC effect. Our ongoing study has demonstrated that CHO-gmt mutants (including CHO-gmt1 and 5) can be adapted to suspension culture in protein-free media with growth profiles similar to that of wild-type CHO-K1 cells.
CHO-gmt5 is the only CHO mutant reported so far that lacks both CST and Gfr. As a result, glycoproteins expressed on the cell surface or secreted into the medium by CHO-gmt5 are free of both sialic acid and fucose. Therefore, these cells offer a rare opportunity for studying the impacts of sialic acid and fucose on the functions of many glycoproteins. For example, glycoproteins expressed by CHO-gmt5 cells will not contain Lewis x/a and sialyl Lewis x/a structures. The biological functions of sialic acid and fucose attached to a particular glycoprotein can be studied by comparing it with the same protein produced by the wild-type cells.
Materials and methods

Materials
Monoclonal anti-HA antibody (Clone HA-7) and rabbit polyclonal anti-B4GalTI antibodies were purchased from Sigma (St Louis, MO). Rabbit polyclonal antibodies for giantin, GM130, ManII and TGN46 were purchased from Abcam (Cambridge, UK). Biotinylated AAL was purchased from Vector Laboratories (Burlingame, CA). FITC-conjugated PNA was purchased from EY Laboratories (San Mateo, CA). AlexaFluor dye-conjugated secondary probes, including goat anti-mouse IgG, goat anti-rabbit IgG and streptavidin, were purchased from Invitrogen (Eugene, OR). Cy3-conjugated streptavidin was purchased from Jackson ImmunoResearch (West Grove, PA). Trypsin was purchased from Promega (Madison, WI). PNGase F was purchased from Calbiochem (San Diego, CA). Hypercarb SPE cartridges (200 mg of sorbent bed weight) were from ThermoFisher Scientific (Waltham, MA). 2,5-Dihydroxybenzoic acid and Sep-Pak Vac C18 cartridge were from Waters Corporation (Milford, MA). Acetic acid, ammonium bicarbonate, hydrochloric acid, methyl iodide, sodium acetate and NaOH were all of analytical reagent grade from Merck (KGaA, Germany). Acetonitrile, dimethyl sulfoxide and methanol were of high-performance liquid chromatography (HPLC) grade from Merck. Chloroform was of HPLC grade from Fisher Scientific (Pittsburgh, PA). Ultrapure water (Sartorius, Goettingen, Germany) was used throughout the analysis.
Cell culture and transfection of the ZFN constructs CHO-gmt1 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (both from Invitrogen, Auckland, CA), at 37°C with 5% CO 2 . Prior to transfection, 5 × 10 5 cells were seeded into each well of 6-well plates and cultured overnight. The constructs for expressing the pair of ZFNs were transiently transfected into CHO-gmt1 cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. In each transfection, a total of 4 µg of plasmid DNA (2 µg for each ZFN) and 10 µL of Lipofectamine 2000 reagent in the 500 µL serum-free DMEM were added to each well containing 2 mL of medium. After overnight incubation, the transfection reagent was replaced with the normal culture medium and cultured for 2 days before single-cell cloning into 96-cell plates.
Constructs for human Gfr SLC35C1 and its variants
The human Gfr Slc35c1 (database accession number: NM_018389) was synthesized by reverse transcribed (RT)-PCR. Briefly, RNA was extracted from HEK293 cells using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. mRNA was RT into cDNA using ImProm-II kit (Promega). cDNA encoding SLC35C1 was amplified by PCR with primer pair specific for 5′-and 3′-ends of the coding region. The HA sequence was incorporated into the forward primer. The amplified Slc35c1 cDNA was digested with HindIII and XhoI (New England Biolabs, Ipswich, MA) and ligated into the pcDNA3.1(+) vector. SLC35C1 variants with mutation in the C-terminal sequence (ΔC-tail, CST-tail, ΔCT1, ΔCT2, EM/GG, 3K/3G and EM-CST-tail) were generated by the standard PCR or overlap PCR. SLC35C1 variants with point mutations in the ΔCT2 deletion region or the transmembrane helical regions were generated using site-directed mutagenesis kit (Stratagene, Cedar Creek, TX) according to the manufacturer's instructions. All constructs contain a Kozak sequence (GCCACC) ahead of the start codon and were cloned into the pcDNA3.1 (+) vector using HindIII and XhoI sites. Coding regions of all constructs were sequenced to rule out unwanted mutations. All primers used for cloning the constructs are listed in Table I .
Structure-function analysis of GDP-fucose transporter
Designing the ZFNs to target the Gfr Slc35c1 in CHO cells The "modular assembly" method was used to generate specific ZFNs for targeting the Slc35c1 gene in CHO cells. The open reading frame of the Chinese hamster Gfr Slc35c1 was analyzed using the web-based ZiFiT program provided by the Zinc Finger Consortium [ZiFiT: software for engineering zinc finger proteins (V3.0)] at http://bindr.gdcb.iastate.edu/ZiFiT/ (Sander et al. 2007 ). The ZiFiT output located a DNA sequence in the first exon of the Gfr coding region (5′-tAACCTCTGCCTCAAGTACGTAGGGGTGGCCt-3′) as a potential target site for ZFNs ( Figure 1A) . Two binding sites for ZFNs (underlined) are separated by 6 bp, which is the optimal distance for cleavage by two ZFNs. This sequence perfectly matches the ideal target sequence for 4-fingered ZFNs, which is 5′-NNCNNCNNCNNCxxxxxxGNNGNN GNNGNN-3′. It allows each zinc finger in the left and the right ZFN to bind to a 5′-GNN-3′ DNA triplet ( Figure 1A ). The fingers that bind the 5′-GNN-3′ triplets are the best studied and strong DNA-binding fingers (Segal et al. 1999; Dreier et al. 2000; Liu et al. 2002) . The structural scaffold for the ZFNs was adopted from previous publications (Urnov et al. 2005; Doyon et al. 2008) . Each zinc finger in our ZFNs was designed based on the publicly available information described in the literature. The complete design of the left and the right finger is shown in Figure 1B .
Isolation and characterization of CHO-gmt5 cells, CHO-gmt1 cells with inactivated Gfr Slc35c1 gene Two days after transfection, single cells were seeded in 96-well plates for clone isolation. Genomic DNA from each single clone was isolated and the Gfr Slc35c1 target locus was amplified by PCR. The sequence of the forward PCR primer is 5′-GGCGCCTCTGAAGCGGTCCAGGATCC. The sequence for the reverse PCR primer is 5′-GCCACATGTGAGC AGGGCATAGAAGG. A 520-bp PCR product was generated from the wild-type CHO genomic sequence which can be digested by a restriction enzyme SnaBI (TAC|GTA) around the ZFN restriction site ( Figure 1A ) to give rise to a smaller fragment of 114-bp and a larger fragment of 406 bp. In case, a mutation has occurred at the targeted site by the ZFNs, the PCR product may become resistant to the restriction enzyme. However, for insertion mutants, the PCR products have to be sequenced in order to identify the mutations.
Analysis of the oligosaccharides released from recombinant EPO-FC using MALDI-TOF The recombinant EPO-Fc was produced in CHO-gmt1 and CHO-gmt5 cells as described earlier (Goh et al. 2010) for N-glycan structure analyses. Briefly, the Fc region from human IgG1 was fused to the C-terminus of EPO by overlap PCR. The PCR product that encodes the EPO-Fc fusion was cloned into pcDNA3.1 with a Kozak sequence placed the upstream of the translation start codon ATG. The EPO-Fc construct was transiently transfected into CHO-gmt1 and CHO-gmt5 cells. Recombinant EPO-Fc produced was purified with a protein A column. An amount of 100 μg of purified EPO-Fc was used for carbohydrate structure analysis. The carbohydrates liberated from the EPO-Fc by PNGase F were analyzed by MALDI-TOF mass spectrometry analysis as described previously (Lim et al. 2008 ).
Immunofluorescence microscopy CHO-gmt5 cells were plated on glass coverslips in 6-well plates and transfected next day using FuGene 6 reagent (Roche, Indianapolis, IN) with plasmid constructs for different SLC35C1 variants. Two days after transfection, cells were washed with phosphate-buffered saline (PBS), fixed with 4% paraformaldehyde (PFA) (diluted from 16% methanol-free PFA from Thermo Scientific, Rockford, IL) in PBS for 10 min and permeabilized by 0.1% Triton X-100 (Sigma) in PBS for 5 min. After washing with PBS twice, cells were blocked with Carbo-Free blocking solution (Vector Laboratories, Burlingame, CA), briefly rinsed with PBS and then incubated with PBS containing 1% bovine serum albumin (BSA) and a monoclonal anti-HA antibody (5 µg/mL final concentration) as well as a Golgi marker antibody at an appropriate dilution for 1 h. For experiments involving the analysis of SLC35C1 activity, biotinylated AAL (5 µg/mL final concentration) was included in the primary antibody mixture. The coverslips were then washed three times in PBS and incubated with secondary antibodies, i.e. AlexaFluor 488 conjugated goat antimouse IgG (for the detection of HA-SLC35C1) and AlexaFluor 594 conjugated goat anti-rabbit IgG (for the detection of Golgi marker), as well as AlexaFluor 647 conjugated-streptavidin for experiments involving biotinylated AAL. In all experiments, Hoechst 33342 (Invitrogen, Eugene) at 2 µg/mL (final concentration) was included in the secondary antibody mixture to stain the nuclei. Finally, the coverslips were washed four times in PBS and then mounted onto glass slides using ProlongGold antifade medium (Invitrogen, Eugene). Fluorescence images were taken using a Carl Zeiss LSM 510 META confocal microscope with a ×63 PLAN-Apochromat objective (1.40 NA) immersed in oil. All AAL images within the same set of experiments were acquired under constant imaging parameters. Representative areas were cropped with LSM Image Brower and used to produce the final figures. For localization analysis of SLC35C1 within the Golgi, images were taken at 10 successive optical slices in the Z-direction (0.41 µm thickness per slice) and used to produce the final figure. FACS analysis of cell surface fucosylation CHO-gmt5 cells were transfected with different SLC35C1 constructs in 12-well plates using the method described in the Immunofluorescence microscopy section. Two days after transfection, cells were washed with PBS and harvested using PBS containing 2 mM ethylenediaminetetraacetic acid (EDTA). After washing with PBS, cells were fixed with 4% PFA (diluted from 16% methanol-free PFA, Thermo Scientific) in PBS for 10 min. After washing with PBS twice, cells were incubated with Carbo-Free blocking solution for 30 min, and then incubated with PBS containing 1% BSA and 5 µg/mL of biotinylated AAL for 30 min. After two washes with PBS, cells were incubated in PBS containing 1% BSA and 5 µg/mL Cy3-conjugated streptavidin for 30 min. Finally, cells were washed twice in PBS and analyzed by a BD LSR II FACS analyzer. For each run, 10,000 events were recorded. AAL-positive region was gated based on untransfected CHO-gmt5 cells and cells transfected with a full-length SLC35C1 construct. Under such gating parameters, CHO-gmt5 cells transfected with a T306R construct had <0.5% population in the AAL-positive region. To control for transfection efficiency, a separate set of transfections were done with each SLC35C1 construct mixed with a GFP construct at a 10:1 ratio. Cells were stained by the same method and GFP fluorescence was analyzed by FACS. Similar GFP fluorescence profiles were obtained for all transfections, suggesting comparable transfection efficiencies for all constructs.
Representative FACS results from the same batch of experiments were used to produce the final figures. 
